Liquid Biopsy/Circulating DNA Topic Track

As circulating cell-free DNA (cfDNA) testing continues to make exciting strides forward, it is critical that laboratory medicine professionals understand the utility and limitations of these assays. This Topic Track delves into the latest progress in cfDNA testing, from its use in prenatal screening and liquid biopsies to new applications in organ transplantation monitoring and advances in analytical approaches.

Monday

*Brown Bag Session: Prenatal Screening for Down Syndrome: From Maternal Serum Screening to Cell-Free Fetal DNA Testing 42117 (Repeats as 52217)

Speaker: Waddah Katrangi, Mayo Clinic, Rochester, MN.

*Brown Bag Session: Liquid Biopsies: The Techniques and Applications 42122 (Repeats as 52222)

Speaker: John Mills, PhD, Mayo Clinic, Rochester, MN.

Tuesday

*Brown Bag Session: Adoption Trends of Liquid Biopsy Technologies 43106 (Repeats as 53206)

Speaker: Divyaa Ravishankar, Frost & Sullivan, San Antonio, TX.

Personalized, Genotype-Directed Treatment and Liquid Biopsy for Non-Small Cell Lung Cancer (NSCLC) 34210

Molecular and personalized genetic tests are expanding in the routine laboratory. Circulating nucleic acids, namely extra-cellular DNA or RNA molecules present in human circulation, serve as versatile biomarkers for achieving blood-based molecular diagnostics for the investigation of fetal health, cancers, other pathologies, and post-transplantation complications. Recently, there have been some exciting advances made in relation to circulating cell-free nucleic acid analysis, resulting in cutting-edge noninvasive applications for personalized diagnostics. In this session, the participant will learn about the recent updates in noninvasive prenatal testing and the latest applications of circulating nucleic acid analysis, including approaches for organ transplantation monitoring, approaches to determine the anatomical location of cancers and other diseases, as well as the advances in analytical approaches available, including droplet digital PCR, nanopore sequencing, and methylome analysis.

Moderator: Zhen Zhao, PhD, NIH Clinical Center, Bethesda, MD.

Speakers: Current Molecular Diagnostics for NSCLC, Kingshuk Das, UCLA, Los Angeles, CA; Emerging Liquid Biopsy Platforms to Detect Actionable Mutations in NSCLC, David Wong, UCLA, Los Angeles, CA; Ongoing Clinical Trials for Advanced NSCLC at the National Institutes of Health, Udayan Guha, MD, PhD, National Cancer Institute, Bethesda, MD.

Wednesday

Precision Medicine Delivered by Advances in Circulating Cell-Free DNA Diagnostics 34212

Molecular and personalized genetic tests are expanding in the routine laboratory. Circulating nucleic acids, namely extra-cellular DNA or RNA molecules present in human circulation, serve as versatile biomarkers for achieving blood-based molecular diagnostics for the investigation of fetal health, cancers, other pathologies, and post-transplantation complications. Recently, there have been some exciting advances made in relation to circulating cell-free nucleic acid analysis, resulting in cutting-edge noninvasive applications for personalized diagnostics. In this session, the participant will learn about the latest applications of circulating nucleic acid analysis, including its utility in organ transplantation monitoring, and in determining the anatomical location of cancers and other diseases. Current strategies for the use of cell free DNA for prenatal screening will be discussed as well as barriers to implementation. The advances in analytical approaches, including droplet digital PCR, nanopore sequencing, and methylome analysis will also be reviewed.

Moderator: Rossa Chiu, MBBS, PhD, The Chinese University of Hong Kong, Shatin, New Territories.

Speakers: Prospective cfDNA-based Prenatal Screening in the General Pregnancy Population Offered by Primary Obstetrical Care Providers in Rhode Island, Glenn Palomaki, PhD, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI; Graft-Derived Cell-Free DNA as a Biomarker in Organ Transplantation, Michael Oellerich, MD, George-August University, Goettingen, Germany; Liquid Biopsy as a Total Body Scan: Unravelling the Sites of Cancer and Other Pathologies, Rossa Chiu, MBBS, PhD, The Chinese University of Hong Kong, Shatin, New Territories.


*About Brown Bag sessions: These small discussion settings provide intimate exchanges between participants and experts. Expect lively conversation, dialogue, and debate, as well as Q&As. Attendance is limited to 10 participants. Advance registration and fees are required.